Tempest Therapeutics has secured FDA approval to move forward with a Phase 3 clinical trial for its cancer drug amezalpat in combination with atezolizumab and bevacizumab for first-line hepatocellular carcinoma (HCC). The company is optimistic about the trial’s success based on positive results from the Phase 2 study.